Strongbridge biopharma plc (SBBP)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenues:
Total revenues

21,712

18,027

7,046

-

-

-

-

Cost and expenses:
Cost of sales (excluding amortization of intangible asset)

3,822

3,986

1,483

-

-

-

-

Selling, general and administrative

49,058

63,336

36,292

14,875

22,719

-

-

Research and development

30,903

25,441

17,268

20,023

20,135

5,844

2,534

Amortization of intangible asset

5,022

7,187

5,022

-

-

-

-

General and administrative

-

-

-

-

-

4,588

2,658

Impairment of intangible asset

-

-

20,723

15,828

-

-

-

Total cost and expenses

88,805

99,950

80,788

50,726

42,854

-

-

Total operating expenses

-

-

-

-

-

10,432

5,192

Operating loss

-67,093

-81,923

-73,742

-50,726

-42,854

-10,432

-5,192

Other income (expenses), net:
Unrealized gain (loss) on fair value of warrants

-11,386

-16,337

30,218

-638

-

-

-

Income from field services agreement

12,616

-

-

-

-

-

-

Expense from field services agreement

6,652

-

-

-

-

-

-

Interest expense

-

12,515

4,313

20

-

-

-

Foreign exchange loss

-

-

-

-69

-124

-204

-570

Loss on extinguishment of debt

-

-21,549

-3,545

-

-

-

-

Gain on sale of subsidiary

-

130,832

-

-

-

-

-

Other income, net

2,060

1,205

106

-1,180

-1,105

486

282

Total other income (expenses), net

19,410

114,310

-37,970

-631

-1,229

282

-288

Loss before income taxes

-47,683

32,387

-111,712

-51,357

-44,083

-10,150

-5,480

Income tax expense

1,768

536

1,771

-2,638

-450

-480

-93

Net income (loss)

-

-

-

-48,719

-43,633

-9,670

-5,387

Net income (loss) attributable to non-controlling interest

-

-

-

-122

-53

-

-92

Net loss

-49,451

31,851

-113,483

-48,597

-43,580

-9,670

-5,295

Unrealized gain on marketable securities

3

-

-

-

-

-

-

Comprehensive loss

-49,448

31,851

-113,483

-

-

-9,670

-5,295

Net loss attributable to ordinary shareholders:
Basic and diluted

-

-

-

-

-

-

-5,295

Basic

-49,451

31,851

-113,483

-48,597

-43,580

-9,670

-

Diluted

-60,837

15,514

-113,483

-49,236

-43,580

-9,670

-

Net loss per share attributable to ordinary shareholders:
Basic (in dollars per share)

-0.91

0.69

-3.11

-2.26

-2.62

-1.20

-

Diluted (in dollars per share)

-1.10

0.31

-3.11

-2.27

-2.62

-1.20

-

Basic and diluted (in dollars per share)

-

-

-

-

-

-

-0.88

Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:
Basic and diluted

-

-

-

-

-

-

6,017

Basic (in shares)

54,182

46,297

36,544

21,550

16,606

8,043

-

Diluted (in shares)

55,383

49,724

36,544

21,655

16,606

8,043

-

Product
Total revenues

21,676

18,027

7,046

-

-

-

-

Royalty
Total revenues

36

-

-

-

-

-

-